Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure
- 23 February 2006
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 47 (6), 1108-1116
- https://doi.org/10.1016/j.jacc.2005.10.064
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Folate Therapy and In-Stent Restenosis after Coronary StentingNew England Journal of Medicine, 2004
- Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline resultsNephrology, 2004
- Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?Kidney International, 2002
- Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitaminsKidney International, 2000
- Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patientsAtherosclerosis, 1996
- High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patientsKidney International, 1996
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementationAtherosclerosis, 1995
- A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.Stroke, 1994
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986